ADC Therapeutics SA (ADCT)
1.22
-0.08
(-6.15%)
USD |
NYSE |
Sep 09, 16:00
1.22
0.00 (0.00%)
After-Hours: 16:48
ADC Therapeutics Enterprise Value : 64.13M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 64.13M |
| September 04, 2026 | 71.77M |
| September 03, 2026 | 66.67M |
| September 02, 2026 | 66.67M |
| September 01, 2026 | 56.48M |
| August 31, 2026 | 47.56M |
| August 28, 2026 | 43.74M |
| August 27, 2026 | 41.19M |
| August 26, 2026 | 32.27M |
| August 25, 2026 | 30.99M |
| August 24, 2026 | 21.45M |
| August 21, 2026 | 25.46M |
| August 20, 2026 | 20.81M |
| August 19, 2026 | 30.99M |
| August 18, 2026 | 29.72M |
| August 17, 2026 | 38.64M |
| August 14, 2026 | 27.17M |
| August 13, 2026 | 32.27M |
| August 12, 2026 | 55.20M |
| August 11, 2026 | 48.83M |
| August 10, 2026 | 42.46M |
| August 07, 2026 | 42.46M |
| August 06, 2026 | 42.46M |
| August 05, 2026 | 34.81M |
| August 04, 2026 | 38.64M |
| Date | Value |
|---|---|
| August 03, 2026 | 32.27M |
| July 31, 2026 | 32.27M |
| July 30, 2026 | 39.91M |
| July 29, 2026 | 38.64M |
| July 28, 2026 | 39.91M |
| July 27, 2026 | 43.74M |
| July 24, 2026 | 45.01M |
| July 23, 2026 | 53.93M |
| July 22, 2026 | 56.48M |
| July 21, 2026 | 60.30M |
| July 20, 2026 | 59.03M |
| July 17, 2026 | 70.50M |
| July 16, 2026 | 70.50M |
| July 15, 2026 | 61.58M |
| July 14, 2026 | 55.20M |
| July 13, 2026 | 57.75M |
| July 10, 2026 | 62.85M |
| July 09, 2026 | 64.13M |
| July 08, 2026 | 61.58M |
| July 07, 2026 | 70.50M |
| July 06, 2026 | 57.75M |
| July 02, 2026 | 50.11M |
| July 01, 2026 | 43.74M |
| June 30, 2026 | 34.81M |
| June 29, 2026 | 16.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 33.40B |
| AC Immune SA | 164.92M |
| CRISPR Therapeutics AG | 3.714B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.56M |
| Revenue (Quarterly) | 19.25M |
| Total Expenses (Quarterly) | 35.81M |
| EPS Diluted (Quarterly) | -0.1069 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -86.06% |
| Earnings Yield | -54.39% |
| Normalized Earnings Yield | -67.81 |